Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.17 USD | -1.50% | -5.17% | -46.22% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 2,604 | 1,463 | - | - |
Enterprise Value (EV) 1 | 2,140 | 984.9 | 769.7 | 1,463 |
P/E ratio | -4.7 x | -6.19 x | -5.85 x | -5.37 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | 40.4 x |
EV / Revenue | - | - | - | 40.4 x |
EV / EBITDA | -8.51 x | -4.02 x | -2.84 x | -4.49 x |
EV / FCF | -13.1 x | -4.66 x | -3.09 x | -4.98 x |
FCF Yield | -7.64% | -21.5% | -32.3% | -20.1% |
Price to Book | 5.77 x | 5.26 x | 3.4 x | 2.61 x |
Nbr of stocks (in thousands) | 152,703 | 159,524 | - | - |
Reference price 2 | 17.05 | 9.170 | 9.170 | 9.170 |
Announcement Date | 24-03-07 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 36.21 |
EBITDA 1 | - | -251.4 | -245 | -271.2 | -325.8 |
EBIT 1 | - | -252.1 | -253.5 | -286.9 | -338.6 |
Operating Margin | - | - | - | - | -935.19% |
Earnings before Tax (EBT) 1 | - | -235.7 | -244.4 | -284.3 | -418.9 |
Net income 1 | -130.9 | -235.9 | -237.3 | -270.8 | -323 |
Net margin | - | - | - | - | -892.1% |
EPS 2 | -0.6100 | -3.630 | -1.482 | -1.566 | -1.706 |
Free Cash Flow 1 | - | -163.4 | -211.5 | -249 | -293.5 |
FCF margin | - | - | - | - | -810.54% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - |
Announcement Date | 23-05-02 | 24-03-07 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | -56.69 | -113.8 | - | - | - | -62 | - | - |
EBIT 1 | -56.86 | -114 | -60.07 | -62.3 | -65.39 | -67.94 | - | - |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -53.03 | -108.5 | -53.72 | -60.73 | -63.97 | -65.93 | - | - |
Net income 1 | -53.03 | -108.7 | -53.72 | -60.73 | -63.97 | -65.93 | - | - |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | - | -0.7100 | -0.3400 | -0.3745 | -0.3942 | -0.3922 | -0.3800 | -0.3900 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 23-11-01 | 24-03-07 | 24-05-07 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | 464 | 478 | 693 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -163 | -212 | -249 | -294 |
ROE (net income / shareholders' equity) | - | -51.2% | -57.9% | -65.5% | -51.6% |
ROA (Net income/ Total Assets) | - | -51.2% | -53.6% | -58.6% | -47.4% |
Assets 1 | - | 461.2 | 442.5 | 462.4 | 680.9 |
Book Value Per Share 2 | - | 2.950 | 1.740 | 2.700 | 3.520 |
Cash Flow per Share 2 | - | -2.510 | -0.8900 | -0.9500 | - |
Capex 1 | - | 0.12 | 0.1 | 0.1 | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 23-05-02 | 24-03-07 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.22% | 1.46B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NMRA Stock
- Financials Neumora Therapeutics, Inc.